Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports
Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated…
Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated…
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or…
In collaboration with University of Heidelberg, Germany, results from a clinical study of pancreatic cancer are published in the Pancreas…
Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m.…
Summit Therapeutics has completed the half-way stage of dosing of its Duchenne Muscular Dystrophy (DMD) candidate ezutromid in a 48-week…
Ablynx NV [Euronext Brussels and Nasdaq: ABLX] has announced that results from its Phase III HERCULES study of caplacizumab have been selected…
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY…
Researchers just published the first randomized controlled trial ever to show an intervention effective at lowering the risk of dementia.…
Quanticate, a data-focused clinical research organisation (CRO), has launched its centralised statistical monitoring service (https://www.quanticate.com/centralized-statistical-monitoring) as an extension of its…